trations. In contrast, neither androstenedione nor testosterone affected hMR transactivation by aldosterone at a concentration of 10 -10 M . Conclusion: Our study shows for the first time that neither androstenedione nor testosterone has a biological effect on aldosterone-mediated transactivation of the hMR. 17OHP and progesterone have an anti-mineralocorticoid effect in vitro that may clinically lead to an increased requirement of mineralocorticoids in poorly controlled CAH patients.
Introduction
Congenital adrenal hyperplasia (CAH) is a group of disorders affecting adrenal steroidogenesis. The incidence of classic CAH varies between 1 in 10,000 and 1 in 15,000 live births in most Caucasian populations [1] . In about 95% of the cases, CAH is caused by 21-hydroxylase deficiency [2] , resulting in impaired adrenal synthesis of cortisol. Cortisol deficiency triggers a counterregulatory increase in pituitary ACTH secretion leading to accumulation of adrenal steroid precursors before the deficient enzymatic step and increased adrenal androgen production. 21-hydroxylase converts 17-hydroxyprogesterone (17OHP) to 11-deoxycortisol, the penultimate step in cortisol synthesis. Hence, 17OHP accumu-lates and is used as a marker for 21-hydroxylase deficiency.
Classic CAH is commonly subdivided in the salt wasting and simple virilizing forms depending on the residual enzymatic activity. Salt wasting patients have no residual 21-hydroxylase activity leading to severe salt loss, typically after the first week of life, and prenatal virilization of the female external genitalia. Patients with the simple virilizing form of CAH have a residual enzyme activity of 1-2% and usually have sufficient aldosterone production to prevent severe salt loss, whereas glucocorticoid synthesis is severely impaired. In both salt wasting and simple virilizing forms, elevated adrenal androgens cause prenatal virilization of the female external genitalia and postnatal androgen excess in both sexes [2, 3] . Current treatment of CAH consists of lifelong glucocorticoid and, if necessary, mineralocorticoid treatment [4] . Treatment with glucocorticoids restores feedback within the hypothalamus-pituitary-adrenal axis, consequently achieving downregulation of adrenal androgen production. In many patients, however, supraphysiological doses of glucocorticoids are needed to normalize androgen levels.
Untreated and poorly controlled CAH patients are characterized by elevated levels of steroid hormone precursors, including progesterone and 17OHP, and androgens such as androstenedione and testosterone [3, [5] [6] [7] [8] . It has been shown that progesterone and 17OHP have antagonistic properties on the human mineralocorticoid receptor (hMR), and therefore may contribute to mineralocorticoid deficiency in classic CAH patients [9] . The aim of our study was to evaluate the effects of 17OHP, progesterone, androstenedione and testosterone on aldosterone-mediated transactivation and translocalization of the hMR. Furthermore, we studied the effect of the frequent mineralocorticoid receptor p.Ile180Val single nucleotide polymorphism (SNP) on transactivation of the hMR.
Material and Methods

Construction of Plasmids
The hMR cDNA was PCR amplified from the previously used pcDNA3.1-NR3C2 construct [10] using specific primers with Hind III and Eco RV restriction sites for directional cloning into pcDNA6/V5-His-B vector (Invitrogen Corp., Carlsbad, Calif., USA). The p.Ile180Val SNP was recreated in the pcDNA6-hMR construct by site-directed mutagenesis using the QuikChange XL Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene, Amsterdam, The Netherlands). The correct insertion of the hMR construct and the p.Ile180Val SNP as well as the integrity of the cDNA was checked by direct DNA sequencing.
For intracellular localization assays Green Fluorescent Protein (GFP), an autofluorescent genetic reporter, was cloned into pcDNA6. The hMR cDNA and the hMR p.Ile180Val (hMR-I180V) construct were cloned into the pcDNA6-GFP vector using the same restriction enzymes as described above.
In vitro Transactivation Assays
Transactivation of hMR and hMR-I180V by different concentrations of aldosterone was investigated using a MMTV-luciferase assay. Approximately 2.5 × 10 4 COS-7 cells were grown in 500 ml of Dulbecco's minimal essential medium (DMEM) high glucose (4.5 g/l) with L -glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH) and penicillin/streptomycin (PAA Laboratories GmbH) in 24- , or in a 10 -10 M concentration in addition to different concentrations of 17OHP (range 5-1,000 n M ), progesterone (2.5-100 n M ), androstenedione (1-250 n M ) or testosterone (0.5-60 n M ) (Sigma Aldrich). Concentrations of 17OHP, progesterone, androstenedione and testosterone used in the assays were based on biochemical findings in CAH patients [5] [6] [7] [8] .
To evaluate the transactivational potential of 17OHP, progesterone, androstenedione and testosterone on the hMR in the absence of aldosterone, transfected cells were also incubated in 500 μl of full DMEM supplemented with different concentrations of these steroids.
Cells were lysed in 100 μl of passive lysis buffer (Promega). Consequently, 30 μl of cell lysate was used for the measurement of firefly and renilla luciferase activity, with a luminometer (Berthold, Bad Wildbad, Germany), using the Dual-Luciferase ® Reporter Assay System (Promega) according to manufacturer's standard protocol. The hMR transactivation was calculated by the ratio of the steroid-dependent (firefly) luciferase and the steroid independent renilla (luciferase). Luciferase/renilla ratios were normalized for luciferase activity driven by pGL3-Basic. Data were normalized for the transactivation by a 10 -10 M aldosterone concentration and are presented as fold transactivation compared to the transactivation by 10 -10 M aldosterone (transactivation by 10 -10 M aldosterone was set as 1.0-fold transactivation). All assays were performed in triplicate (n = 9). Statistical analysis was performed using GraphPad Prism software version 5.0 (GraphPad Software, San Diego, Calif., USA). Results were analysed by both linear regression analyses and ANOVA with Bonferroni adjustment for multiple comparisons (all 416 possible comparisons were analysed). Differences between the hMR wild type and the p.Ile180Val construct were analysed using a t test. p < 0.05 was considered significant.
Intracellular Localization
The transactivational potential of the hMR-GFP construct was evaluated to ensure comparable transactivational potential to the hMR construct in the presence of 10 -10 M concentrations of aldosterone. The hMR-GFP construct was used for an intracellular localization assay. Approximately 2 × 10 5 COS-7 cells were grown on glass coverslips in 6-well plates containing 2 ml of DMEM high glucose (4.5 g/l) with L -glutamine (PAA Laboratories GmbH) supplemented with charcoal stripped fetal bovine serum (Sigma Aldrich) and penicillin/streptomycin (PAA Laboratories GmbH). Twenty-four hours after seeding, the cells were transiently transfected using FuGene ® HD transfection reagent (Roche Applied Sciences) with 2 μg of hMR-GFP or 2 μg of hMR-I180V-GFP. Forty-eight hours after transfection, cells were treated for 120 min with a combination of 10 -10 M aldosterone and different concentrations of other steroids (17OHP, progesterone, androstenedione and testosterone) to study the effect of these steroids on the intracellular localization of the receptor. Cells were washed three times in 1× phosphate buffered saline (PBS) and fixed in 1 ml 100% methanol at -20 ° C for 15 min. Fixed cells were further washed three more times in 1× PBS and mounted on Vectorshield with 4', 6-diamidino-2-phenylindole (DAPI; exclusively nuclear staining). Results were obtained from three independent transfection experiments in which 150 transfected cells were classified in 4 categories: (1) nuclear, (2) mainly nuclear, (3) equal nuclear and cytoplasmic, and (4) mainly cytoplasmic. Representative images were taken using confocal microscopy (Nikon Instruments Inc., Melville, N.Y., USA). To evaluate if treatment causes a difference in the number of cells counted as nuclear, mainly nuclear, equal nuclear or mainly cytoplasmic, respectively, one-way ANOVA was performed. Statistical analysis was performed using GraphPad Prism software version 5.0.
Results
Transactivation of the Mineralocorticoid Receptor by Aldosterone
Increasing concentrations of aldosterone caused an increase in potent transactivation of both the hMR and hMR-I180V. The dose-dependent effects on the transactivation are shown in a dose-response curve ( fig. 1 ). An estimated concentration for 50% transactivation (EC-50) of the hMR of around 10 -10 M aldosterone was calculated for both the wild type (2.4 × 10 -11 M ) and the p.Ile180Val SNP (1.2 × 10 -11 M ).
Effect of 17OHP, Progesterone, Androstenedione and Testosterone on hMR Transactivation
Increasing concentrations of 17OHP and progesterone inhibited aldosterone-mediated transactivation of the hMR in a dose-dependent fashion ( fig. 2 ) The effect of three different concentrations of 17OHP on the aldosterone-mediated transactivation of the hMR was also evaluated in the p.Ile180Val SNP construct ( fig. 3 ) . The inhibitory effect of 17OHP on hMR-I180V was found to be similar to its effect on the wild-type hMR (p > 0.05). 
Intracellular Localization of the hMR
The transactivation potential of both the hMR-GFP and the hMR construct were compared to assess whether the GFP had altered transactivational properties of the construct prior to performing an intracellular localization assay. The hMR-GFP construct was shown to have equal transactivational properties as the hMR construct (online suppl. fig. 1) .
In untreated cells, the hMR was localized only in the cytoplasm or equally distributed in nucleus and cytoplasm ( fig. 4 a) . Treatment with aldosterone for 120 min resulted in a clear translocation of the hMR with a predominantly nuclear localization.
17OHP and progesterone did not influence the translocation of the hMR to the nucleus in the presence of aldosterone ( fig. 4 b) . Treatment with 17OHP, progesterone, androstenedione or testosterone did not result in significant differences in the intracellular localization of the hMR.
In the presence of aldosterone, the hMR-I180V-GFP was also mainly localized in the nucleus. 17OHP did not inhibit the translocation of the hMR-I180V-GFP to the nucleus in the presence of aldosterone ( fig. 4 c) .
Discussion
We studied the effects of different adrenal steroid hormone precursors and androgens on the transactivational potential and localization of the hMR. Our study shows for the first time that excess concentrations of androstenedione and testosterone do not have a biological effect on the aldosterone-mediated transactivation of the hMR in vitro. Furthermore, 17OHP and progesterone have a strong anti-mineralocorticoid effect in vitro, which confirms previous findings [9] . This study highlights the anti-mineralocorticoid effect of elevated 17OHP concentrations as found in poorly controlled CAH patients.
These findings may have important implications for the clinical care provision. Based on our results, it can be suggested that elevated 17OHP and progesterone concentrations are likely to have an adverse effect on the mineralocorticoid effect in untreated and poorly treated CAH. This may potentially lead to increased requirement of mineralocorticoids and suboptimal control. In contrast, elevated androgens did not influence the mineralocorticoid transactivation in vitro. We therefore hypothesize that elevated androgens per se do not have a clinical relevant effect on mineralocorticoid treatment in the clinical care of CAH.
The current treatment strategy is based on normalizing adrenal androgens to prevent adverse effects of hyperandrogenism. Slightly elevated 17OHP concentrations are generally accepted because of the possible side effects of high dosages of glucocorticoids needed to achieve physiological 17OHP concentrations. Based on our results it can be suggested that lowering of highly elevated 17OHP concentrations may also have an additional positive effect on the dosage of mineralocorticoid treatment and consequently decrease the potential risk of adverse effects of mineralocorticoid treatment such as hypertension. Unfortunately, supraphysiological doses of glucocorticoids are generally necessary to lower 17OHP levels that may lead to adverse effects and longterm complications. Therefore, the treatment goal in CAH patients is normalization of adrenal androgens with slightly elevated 17OHP levels [4] . Elevated renin levels may indicate the need for higher mineralocorticoid doses. However, based on our data, elevated renin concentrations may also reflect the anti-mineralocorticoid effect of elevated 17OHP concentrations. A fine balance between the use of supraphysiological dosages of glucocorticoids, mineralocorticoid treatment and normalizing 17OHP levels has to be achieved to prevent long-term complications of overtreatment with glucocorticoids on one hand and overtreatment with mineralocorticoids on the other hand.
The antagonistic properties of progesterone on the human, rat and sheep mineralocorticoid receptor have been previously described [9, [11] [12] [13] [14] [15] . A 50% inhibition of the maximum transactivation of the mineralocorticoid receptor is caused by progesterone concentrations between 2 and 11 n M [9, [16] [17] [18] . The inhibitory effect of progesterone described in our study is in line with those described in the studies mentioned above. Minor differences between the results of those studies may be explained by different cells and different luciferase constructs used.
The effect of slightly elevated 17OHP concentrations on the hMR have been studied previously [9] . The previously reported concentration of 135 n M , causing a 50% inhibition of transactivation of the hMR by a 10 -9 M aldosterone, is in line with the antagonistic effect of 17OHP on aldosterone-mediated transactivation described in our study. In our study we evaluated the effect of even higher 17OHP concentrations, as found in untreated or poorly controlled CAH patients.
In contrast to the effect on transactivation, the translocation to the nucleus seems not to be affected by 17OHP or progesterone. The physiological human ligand of the hMR is aldosterone. After binding to aldosterone, the hMR undergoes a conformational change and partial dissociation of the ligand binding complex occurs, leading to translocation of the hMR to the nucleus. Within the nucleus, the activated receptors regulate transcription by different pathways including transactivation of target genes [19] [20] [21] [22] [23] . Intracellular localization studies on the hMR have shown that in the absence of steroids the hMR is localized in the cytoplasm and in the nucleus, aldosterone causes a rapid nuclear accumulation of the hMR [19, [24] [25] [26] [27] . Binding of aldosterone to the hMR causes dissociation of several associated proteins from the receptor, followed by dimerization and finally nuclear translocation of the activated receptor. The translocation assay performed in this study showed a similar subcellular localization with a predominant localization of the hMR in the cytoplasm in the absence of steroids. Treatment of the COS-7 cells expressing the hMR-GFP construct with aldosterone causes a quick translocation of the hMR to the nucleus of the cells. However, different concentrations of 17OHP and progesterone in addition to an aldosterone concentration of 10 -10 M do not have an impact on the translocation of the hMR to the nucleus. This finding is in contrast to the described effects of hMR antagonists, such as spironolactone and eplerenone, which inhibit the translocation of the hMR to the nucleus [19] .
The mechanism of the inhibition of aldosterone-mediated transactivation of the hMR by progesterone and 17OHP remains unclear. It has been shown that 17OHP has a relatively high binding affinity for the hMR [9] . Therefore, competitive binding of the hMR between 17OHP and aldosterone, such as in patients with poorly controlled CAH, is very likely. We showed that 17OHP does not inhibit the translocation of the hMR to the nucleus. Therefore, we hypothesize that the anti-mineralocorticoid effect of 17OHP on the hMR is not due to an effect on the translocation of the hMR, but might be caused by effects on the transcription after translocation to the nucleus. It has been suggested by Hellal-Levy et al. [20] that binding of an antagonist to the hMR leads to an inactive conformation of the hMR. Due to instability, this complex of the mineralocorticoid receptor and its antagonist will not be converted into a transcriptionally active conformation [20] . This hypothesis may explain the antagonistic properties of 17OHP and progesterone on the hMR.
The mineralocorticoid receptor p.Ile180Val SNP (rs5522) is one of the most frequent SNPs in the hMR with a frequency of 10.2% of the G allele in a European population (HapMap project, www.hapmap.org). The mineralocorticoid receptor p.Ile180Val SNP has been associated with an increased hypertension risk [28] . As CAH patients have a tendency to develop elevated blood pressure [29, 30] , the role of this SNP in CAH patients might be important with respect to their cardiovascular risk profile. We showed that the hMR p. Ile180Val SNP does not affect transactivation of the hMR by aldosterone. These findings are in line with the results by DeRijk et al. [31] . In addition, 17OHP has the same antagonistic effect on the hMR-I180V SNP as on the wild-type hMR. Thus, the results of this study do not explain the increased hypertension risk in p. Ile180Val.
In conclusion, our study shows for the first time that neither androstenedione nor testosterone have a significant biological effect on the aldosterone-mediated transactivation of the hMR. In contrast, increased 17OHP and progesterone concentrations have an anti-mineralocorticoid effect due to an inhibition of aldosterone-mediated transactivation of the hMR. However, unlike hMR blockers, neither 17OHP nor progesterone inhibits the translocation of the hMR to the nucleus. Further studies are needed to explain the mechanism of this inhibition of transactivation by 17OHP.
